2025-09-14 - Analysis Report
Okay, here's an analysis of Intuitive Surgical (ISRG) based on the provided data, presented in a structured format:

## ISRG (Intuitive Surgical Inc) Analysis

**Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets robotic surgical systems, primarily the da Vinci surgical system.

### 1. Performance vs. S&P 500 (VOO)

*   **ISRG Cumulative Return:** 46.95%
*   **VOO Cumulative Return:** 89.18%
*   **Absolute Divergence (Current):** -42.23% (ISRG is lagging behind VOO)
*   **Relative Divergence:** 65.0 (Indicates that the current divergence is in the higher range of its historical fluctuation relative to VOO).

**Analysis:** ISRG has significantly underperformed the S&P 500 over the period covered. The relative divergence suggests that while the underperformance is notable, it's within the historical range of fluctuation compared to the S&P 500.

### Alpha, Beta Analysis

| Year       | CAGR   | MDD     | Alpha   | Beta  | Cap(B) |
|------------|--------|---------|---------|-------|--------|
| 2015-2017  | -7.0%  | 8.7%    | -9.0%   | 0.7   | 43.6   |
| 2016-2018  | 11.0%  | 63.1%   | 16.0%   | -0.0  | 57.2   |
| 2017-2019  | 32.0%  | 63.1%   | 9.0%    | 0.0   | 70.6   |
| 2018-2020  | 57.0%  | 63.1%   | 30.0%   | -0.0  | 97.8   |
| 2019-2021  | 81.0%  | 62.8%   | 32.0%   | 0.0   | 128.8  |
| 2020-2022  | 10.0%  | 69.8%   | 3.0%    | 0.0   | 95.1   |
| 2021-2023  | 8.0%   | 72.7%   | -12.0%  | 1.6   | 120.9  |
| 2022-2024  | 30.0%  | 72.7%   | 3.0%    | 1.7   | 187.1  |
| 2023-2025  | 16.0%  | 72.7%   | -38.0%  | 0.8   | 161.2  |

*   **CAGR:** Varies significantly over different periods, with high growth in 2019-2021 but lower growth recently.
*   **MDD:** High Maximum Drawdown values indicate significant price volatility.
*   **Alpha:**  Mixed performance, indicating periods of outperformance (positive Alpha) and underperformance (negative Alpha) relative to a benchmark.  The recent negative Alpha suggests underperformance.
*   **Beta:** The Beta values are unstable and high, which indicates unstable company stock compared to the market.
*   **Cap(B):** Market capitalization has generally increased over time, but declined in 2020-2022, indicating company size growth.

**Analysis:** ISRG shows a high degree of volatility. Alpha fluctuates, suggesting that ISRG's returns are not consistently correlated with market movements.

### 2. Recent Price Action

*   **Current Price:** 449.68
*   **Previous Close:** 455.85
*   **Change:** -1.35 (-1.35%)
*   **5-Day Moving Average:** 458.61
*   **20-Day Moving Average:** 466.6475
*   **60-Day Moving Average:** 493.3862

**Analysis:** The price is below all three moving averages, suggesting a short-term downtrend.  The recent price decrease of -1.35% is not extreme, but the continuous decrease is not good sign.

### 3. Technical Indicators & Outlook

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 38.27 (Approaching oversold territory)
*   **PPO:** -0.0411 (Negative, indicating a downtrend)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (3 shares - Safe - MRI:0.33)
*   **Delta_Previous_Relative_Divergence:** 3.5 (Positive, suggesting short-term upward momentum)
*   **Expected Return (%):** 208.0 (High, projecting significant long-term outperformance vs. S&P 500)

**Analysis:** The MRI indicates low market risk.  The RSI is nearing oversold, which could suggest a potential buying opportunity. The positive change in relative divergence provides a mixed signal. The high expected return suggests strong long-term growth potential, but this should be viewed cautiously in light of recent underperformance.

### 4. Recent News & Significant Events

*   **FDA Clearance:** Multiple articles highlight FDA clearance for new features in the da Vinci 5 system, indicating innovation and regulatory approval.
*   **Analyst Attention:** ISRG is attracting investor attention.
*   **Jim Cramer's Opinion:** Jim Cramer is hesitant to "pull the trigger," suggesting some uncertainty.

**Analysis:** Recent news is generally positive, focusing on innovation and regulatory approvals. However, Cramer's comment suggests there may be concerns regarding the stock's current valuation or near-term outlook.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.94)
*   **Target Price (avg/high/low):** 582.10 / 685.00 / 350.00
*   **Recent Rating Changes:** No significant recent changes

**Analysis:** Analyst consensus is generally positive, with a "Buy" rating and a significant average target price well above the current price. This suggests analysts see upside potential for the stock.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출      |
|--------------|------|-----------|
| 2025-07-23   | 1.84 | 2.44 B$   |
| 2025-04-23   | 1.95 | 2.25 B$   |
| 2024-10-18   | 1.59 | 2.04 B$   |
| 2024-07-19   | 1.48 | 2.01 B$   |
| 2025-07-23   | 1.48 | 2.01 B$   |

**Analysis:** Both EPS and revenue have generally been increasing in the last 5 quarters, indicating growth.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $2.44B    | 66.31%        |
| 2025-03-31   | $2.25B    | 64.69%        |
| 2024-12-31   | $2.41B    | 68.04%        |
| 2024-09-30   | $2.04B    | 67.41%        |
| 2024-06-30   | $2.01B    | 68.30%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-06-30   | $17.85B   | 3.69%    |
| 2025-03-31   | $17.11B   | 4.08%    |
| 2024-12-31   | $16.43B   | 4.17%    |
| 2024-09-30   | $15.58B   | 3.63%    |
| 2024-06-30   | $14.71B   | 3.58%    |

**Analysis:**

*   **Revenue:** Steadily increasing, indicating strong demand for Intuitive Surgical's products and services.
*   **Profit Margin:** Consistently high, demonstrating pricing power and efficient operations.
*   **Equity:** Growing, showing the company is building value.
*   **ROE:** Moderate, suggesting the company is generating reasonable returns on equity.

### 7. Overall Summary

*   **Mixed Performance:** ISRG has underperformed the S&P 500 recently, and the current price is in a short-term downtrend.
*   **Positive Fundamentals:** The company has strong revenue growth, high profit margins, and a solid financial position.
*   **Innovation Driver:** The recent FDA approvals and news surrounding the da Vinci 5 system indicate a commitment to innovation.
*   **Analyst Optimism:**  Analysts generally have a "Buy" rating with a significantly higher target price.
*   **Technical Concerns:** The RSI is approaching oversold, but the price is below key moving averages.

**Conclusion:** ISRG presents a mixed picture. While the company's fundamentals and long-term growth potential appear strong, recent underperformance and technical indicators suggest caution in the short term. The analyst's target prices suggest a potential revaluation.

**Recommendation:** Investors should weigh the positive long-term outlook against the potential for short-term volatility and consider dollar-cost averaging if initiating a new position. Further monitoring of earnings and technical indicators is warranted.
